Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.84 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.81 |
| ▸ | CA12 | O43570 | 2/20 | 0.74 |
| ▸ | CA1 | P00915 | 2/20 | 0.74 |
| ▸ | CA2 | P00918 | 2/20 | 0.74 |
| ▸ | CA4 | P22748 | 2/20 | 0.74 |
| ▸ | CA9 | Q16790 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17377994 | 1.00 | PTGS2 (0.85) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL31462318 | 1.00 | PTGS2 (0.85) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL3848188 | 0.99 | PTGS2 (0.85) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL837906 | 0.98 | PTGS2 (0.84) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL5112940 | 0.96 | PTGS2 (0.85) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL2489747 | 0.93 | PTGS2 (0.84) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL6398477 | 0.92 | PTGS2 (1.00) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL11152422 | 0.92 | PTGS2 (1.00) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL11157847 | 0.92 | PTGS2 (1.00) | PTGS2PTGS1HRH4HDAC3HDAC1 | |
| SCHEMBL14346030 | 0.92 | PTGS2 (1.00) | PTGS2PTGS1HRH4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017432-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20190169084-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2018-06-14 | — | — | US | disclosed |
| US-9850183-B2 | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging | Reiley Pharmaceuticals, Inc. (US) | 2017-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | PTGS2 6/4885PTGS1 5/4885HRH4 2009/4885 |
| US-20220017432-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | PTGS2 6/4885PTGS1 5/4885HRH4 2009/4885 |
| US-20190169084-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | PTGS2 6/4885PTGS1 5/4885HRH4 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.